ALLEN ZHIWEI WU

Work Address
Center for Public Health Research
Nanjing University
22 Han Ko Road, Meng Mingwei Tower Rm# 2104
Nanjing, Jiangsu 210093
P.R. China
Email: wzhw@nju.edu.cn, and/or popcon66@yahoo.com

SUMMARY:

Dr. Wu is currently a professor and the director of Center for Public Health Research at Nanjing University. He obtained his Ph.D. from University of Edinburgh in Biochemistry and received his post-doctoral training at New York University in viral immunology. His research interests include humoral immununity to HIV infection, vaccine development and anti-viral research. He and his team have been playing important roles in establishing capacity in anti-viral research and microbicide development in China.

EDUCATION:

1982: B.A., Biological Sciences, Nanjing University, Nanjing, P.R. China.
1991: Ph.D., Biochemistry, University of Edinburgh, Edinburgh, UK.

PROFESSIONAL EXPERIENCE:

2005-present: Professor and Director, Center for Public Health Research, Nanjing University, Nanjing, P.R. China.
2005-present: Adjunct associate professor, New York University, New York, USA.
2000-2005: Sr. Investigator, at Leon Levy Dental Research Center, Dept. of Biochemistry, School of Dental Medicine, University of Pennsylvania.
1997- 2000: Staff Scientist, Center for Biomedical Research, The Population Council, Rockefeller University.
1994- 1997: NIH Fellow, Dept. of Microbiology, New York University Medical School, NY, NY.
1992-1994: Aaron Diamond Fellow, Public Health Research Institute, New York University Medical School, NY, NY.
1990- 1992: Postdoctoral Fellow, Public Health Research Institute, NYU Medical School, NY, NY.
1986- 1990: Ph.D. candidate, University of Edinburgh, Edinburgh, UK.

HONORS:

Academic Staff Award, PRC, 1985;
Overseas Research Student Award (ORS), UK, 1987-1989;
Wellcome Trust Fellowship, London, UK, 1988-1989;
Melville Assistantship, Scotland, UK, 1988-1989;

Aaron Diamond Fellow, USA, 1992-4;
NIH Fellow, USA, 1995.

CURRENT FUNDINGS:

1. National Research Infrastructure Grant (The 985 Grant, China). 2005-2009. (PI), RMB 2,000,000/yr.
2. National Major Research Grant (Ministry of Sciences and Technologies, China) (Program Project). Immunologic correlates in AIDS patients under HAART therapy. 2006-2010, RMB 400,000/yr.
3. Corporative Agreement with New York University. Development of anti-gp-340 monoclonal antibodies. 2006-2007, USD30,000/yr.
4. "11-5" National Major Research Development Grant (Ministry of Health), Development of Topical Microbicides. 2008-2010. (PI), RMB5,000,000/yr.
5. National Science Foundation of China, Mechanisms of HIV-1 selective transmission. 2008-2011. RMB100,000/yr; Anti-HIV-1 activity of N-SRCR. 2007-2009. RMB97,000/yr.
6. British Council/DEFID. Developing public health strategies to effectively tackle the spread of HIV/AIDS among the economic migrants of China. 2007-2010 (PI), RMB280,000/yr.

SELECTED PUBLICATIONS:

Wu, Z.W., S.C. Kayman, K. Revesz, H.C. Chen, S. Warrier, S.A. Tilley, J. McKeating, C. Shotton and A. Pinter (1995). Characterization of neutralization epitopes in the V2 region of HIV-1 gp120: role of conserved glycosylation sites in the correct folding of the V1/V2 domain. *Journal of Virology*. 69: 2271-2278.

Pinter, A., W.J. Honnen, S.C. Kayman, O. Troshev and Z. Wu (1998). Potent Neutralization of primary HIV-1 isolates by antibodies directed against epitopes present in the V1/V2 domain of HIV-1 gp120. *Vaccine*. 16(19): 1803-11.

Wu, Z. W., D. Van Ryke, C. Davis, W.R. Abrams, I. Chickein, J. Magnani, and D. Malamud (2003). Salivary agglutinin (SAG) inhibits HIV-1 infectivity through interaction with the envelope glycoprotein. *AIDS Res and Human Retroviruses* 19:201-209.

Wu, Z.W., Z.W. Chen and D.M. Phillips (2003). Human urogenital epithelial cells capture cell-free HIV-1 viruses and transmit the virus to CD4+ cells ï Implications to mechanisms of sexual transmission. *J Inf Diseases* 188:1473-1482.

Wu, Z.W., E. Golub, W. Abrams and D. Malamud (2004). Gp340 binds to a V3 sequence important for chemokine coreceptor interaction *AIDS Res and Human Retroviruses* 20:600-607.

Wu, Z.W., S. Lee, W. Abrams, D. Weissman and D. Malamud (2006). The N-Terminal SRCR-SID Domain of gp-340 Interacts with HIV Type 1 gp120 Sequences and Inhibits Viral Infection. *AIDS Research and Human Retroviruses*. 22: 508-515.

Cummins, J.E., Jr., L. Christensen, J.L. Lennox, T.J. Bush, Z.W. Wu, D. Malamud, T. Evans-Strickfaden, C.E. Hart, C.S. Dezzutti (2006). Mucosal innate immune factors in the female genital tract are associated with vaginal HIV-1 shedding independent of plasma viral load. *AIDS Research and Human Retroviruses* .22: 788-795.

Wu, Z.W., S. Lee, S. Davis, and D. Malamud. (2008) N-SRCR, a truncation fragment of gp-340 inhibits HIV-1 infection by blocking virus co-receptor binding. (Submitted).

SELECTED MEETING PRESENTATIONS AND POSTERS:

Zhiwei Wu, Zhiwei Chen, and David M. Phillips. Human urogenital epithelial cells capture cell-free HIV-1 and transmit the virus to CD4+ cells ï Implications to mechanisms of sexual transmission. 10th Conference on Retroviruses and Opportunistic Infections. 2003 Boston, MA.

C. Resnick, D. Malamud, Z. Wu, and C. Davis. Expression of a Salivary Anti-HIV Protein (gp-340) In Eukaryotic Cells. 32nd Annual Meeting and Exhibition of the AADR. 2003. San Antonia, USA.

D. Malamud, Z. Wu, C. Dezzutti, and D. Weissman. GP340: a novel microbicide from the innate immune system. Microbicide 2004. 2004. London, UK.

Wu, Z.W., G.F. Fu, Y.Y. Hou, and Z.W. Chen. An in vitro system for HIV-1 selective transmission using human genital epithelial cells. 14th International Symposium on HIV and Emerging Infectious Diseases. 2006 Toulon, France.

Malamud, D., C. Barber, W. Abrams, Z.W. Wu, E. Stoddard, G. Cannon and D. Weissman. Identification of the active site on gp340 involved in inhibition of HIV-1 infection. Microbicides 2006. Cape Town, South Africa.